Fresh bone-lesion flow cytometry supports Langerhans cell histiocytosis in two pediatric cases
Summary
Two pediatric LCH case reports describe flow cytometry on fresh bone-lesion tissue alongside pathology. This offers early feasibility evidence, without establishing diagnostic sensitivity or replacing integrated diagnosis.
Source Date
October 8, 2026
Source checked
October 10, 2026
Event Type
Peer-reviewed case reports
Event Date
October 8, 2026
Geography
Pediatric case series
Commercial Regulatory Status
Clinical research report; no regulatory authorization established.
Related CFCM Topics
Tissue cytometry; LCH; Academy; Validation; Technology Radar
Category
Technology
Primary source
Read the source →Facts supported by cited sources
Fresh tissue alongside pathology
Chun et al. reported two pediatric bone-lesion cases in BMC Pediatrics on 8 October 2026. Abnormal populations represented 30.67% and 16.09% of analyzed nucleated-cell events.
The cells expressed CD1a and CD207, with findings concordant with histopathology and immunohistochemistry. DOI: 10.1186/s12887-026-07803-5.
Claims Requiring Caution
Two cases cannot estimate diagnostic sensitivity, specificity or a clinical detection limit. The reported percentages describe the analyzed samples. Sampling, tissue dissociation and cellular recovery affect what reaches the cytometer.
Why It Matters
Why it matters for CFCM
Fresh-lesion cytometry may contribute an additional immunophenotypic view when tissue is available. Plan specimen allocation with pathology and report the analyzed denominator explicitly. The practical lesson is to integrate complementary evidence and retain the limits of a small case series.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →